CMN Weekly (15 October 2021)
Oct. 15, 2021
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Sarepta Therapeutics
Main focus: Gene therapies and gene editing for the treatment of muscular dystrophy
Company stage: Clinical
Diseases: Duchenne Muscular Dystrophy (DMD)
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:SRPT)
Location: Cambridge, MA, USA
Website: https://www.sarepta.com/
Pipeline: https://www.sarepta.com/products-pipeline/pipeline
Partnerships: Genevant Sciences, GenEdit
Sarepta Therapeutics is a clinical stage, publicly traded biotech company. The company focuses on many biotherapeutic areas, some of which include gene editing. Sarepta is using CRISPR-Cas9 as a tool for treating Duchenne muscular dystrophy. It has a collaboration with Genevant Sciences for the delivery of CRISPR constructs and collaborations with Duke University and Harvard University to develop gene-editing methods.
